Emergent BioSolutions Inc (EBS)

HEALTH CARE: BIOTECHNOLOGY & LIFE SCIENCES
SIC: PHARMACEUTICAL PREPARATIONS

400 PROFESSIONAL DR, SUITE 400 GAITHERSBURG, MD 20879

Emergent BioSolutions Inc. develops, manufactures, and commercializes immunobiotics such as vaccines and immune globulins that assist the body's immune system. The company's biodefense segment develops, manufactures, and commercializes drugs such as BioThrax, a vaccine for the prevention of anthrax, for use against biological agents. Other products in preclinical development include drugs for the treatment of patients after they are exposed to anthrax and botulinum toxin. Emergent's commercial segment develops products for use against infectious diseases. These include a single-dose typhoid vaccine in phase II clinical development; a hepatitis B vaccine in phase II clinical development, and a group B streptococcus vaccine for women of childbearing age for protection of the fetus and newborn babies, which is in phase I clinical trials. Emergent is also developing chlamydia and meningitis B vaccines. Emergent primarily works for the U.S. Defense and Health & Human Services departments. It has collaboration agreements with the British Health Protection Agency for the development of a human botulinum immune globulin candidate and with Sanofi Pasteur for the development of meningitis B vaccine candidate.

Data based on most recent fiscal year report
Market Cap2.959 Billion Shares Outstanding51.62 Million Avg Volume563.866 Thousand
1-Yr BETA vs S&P TR0.899 Current Ratio3.1 Quick Ratio2.07
View SEC Filings from EBS instead.

View recent insider trading info

Funds Holding EBS (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding EBS BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

11.8 Thousand total shares from 2 transactions

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

HARSANYI ZSOLT

  • Director
36,273 2020-01-16 2

BAILEY SUE

  • Director
46,333 2019-12-12 2

ZOON KATHRYN C

  • Director
17,412 2019-11-18 4

RICHARD RONALD

  • Director
26,699 2019-11-07 2

WHITE MARVIN L PRESIDENT AND CEO

  • Officer
  • Director
0 2019-11-01 0

EL-HIBRI FUAD

  • Director
4,058,738 2019-08-12 1

MULLIGAN SEAMUS

  • Director
1,102,788 2019-08-08 2

SARAN ATUL EVP, CORP DEV, GC & SECRETARY

  • Officer
30,495 2019-08-07 2

SULLIVAN LOUIS W

  • Director
5,120 2019-06-26 2

ABDUN-NABI DANIEL BOARD OF DIRECTORS

109,351 2019-06-25 2

NIEDERHUBER JOHN BOARD OF DIRECTORS

0 2019-06-01 0

JOULWAN GEORGE A

  • Director
31,950 2019-05-23 1

HAUER JEROME M

  • Director
18,324 2019-05-23 1

EMERGENT BIOSOLUTIONS INC.

  • SEAN KIRK, EVP, MANUFACTURING
13,604 2019-05-23 1

ELSEY R DON

  • Director
104,456 2019-05-15 0

KRAMER ROBERT PRESIDENT AND CEO

  • Officer
111,394 2019-05-08 2

STREI KATHERINE EVP, CHIEF HR OFFICER

  • Officer
22,188 2019-05-08 2

LINDAHL RICHARD S EVP, CHIEF FINANCIAL OFFICER

  • Officer
20,937 2019-05-08 2

HAVEY ADAM EVP, BUSINESS OPERATIONS

  • Officer
32,240 2019-03-11 3

INTERVAC, L.L.C.

  • 10% Owner
0 2016-08-01 0

LABINGER BARRY EVP, BIOSCIENCES DIV.

  • Officer
25,182 2015-11-13 1

CHATFIELD STEVEN EVP, BIOSCIENCES

  • Officer
28,000 2013-03-14 0

ALLBAUGH JOE M

  • Director
523,713 2011-07-01 0

KEESE KYLE EVP, BIOSCIENCES DIVISION

  • Officer
18,759 2011-03-15 0

LOCKHART STEPHEN SVP PRODUCT DEVELOPMENT

  • Officer
6,980 2010-11-11 0

BIOPHARM, L.L.C.

  • 10% Owner
No longer subject to file 2010-05-27 1

ESPOSITO DENISE CLO

  • Officer
0 2009-03-10 0

BIOLOGIKA, L.L.C.

  • MEMBER 13(D) GROUP OWNING >10%
1,399,764 2008-06-04 1

MICHIGAN BIOLOGIC PRODUCTS, INC.

  • MEMBER 13(D) GROUP OWNING >10%
1,328,018 2008-01-14 1

Insider Transactions Last 60 Days

Reporting Owners Transaction Date Transaction Code Shares Share Price Acquired or Disposed Shares Owned Following Transaction Combined shares owned after filing Direct/Indirect Ownership 10b-5

HARSANYI ZSOLT - Director

2020-01-16 S 3,435 $55.00 d 36,273 36,273.00 direct

BAILEY SUE - Director

2019-12-12 S 8,375 $53.46 d 46,333 46,333.00 direct
Click here to report any possible errors with this stock listing.

Elevate your investments